PTC Therapeutics (PTCT) Shares Moved, What Is Behind The Attention Today?
PTC Therapeutics (PTCT) is gaining attention due to an expected completion of the ST-920 approval process in Q4 2026, supported by positive Phase 1/2 data. Despite recent short-term share price dips, its long-term performance remains strong, and analysts view the stock as undervalued, forecasting a fair value of $96.93 against its current $70.52. However, risks include reliance on a few products and ongoing losses that might necessitate further funding.
Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative?
Sana Biotechnology reported a narrower net loss and reduced loss per share for Q2 2026 and the first half of the year, signaling improved cost controls and financial efficiency. While this strengthens the investment case by easing concerns about cash burn, the fundamental drivers remain clinical progress and partnerships. Investors should still consider the short cash runway and "going concern" doubts.
Eupraxia Pharmaceuticals Market Sentiment
This article provides an overview of market sentiment for Eupraxia Pharmaceuticals (EPRX), including analyst consensus, short interest, options flow, and insider activity. It highlights that 6 analysts have a "Buy" consensus with an average price target of $16, indicating a significant upside. The article also lists recent analyst actions with their ratings and price target changes.
Somerville Kurt F Invests $8.17 Million in Vertex Pharmaceuticals Incorporated $VRTX
Somerville Kurt F acquired a new stake of 16,441 shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the second quarter, valued at approximately $8.17 million. This investment makes Vertex Pharmaceuticals its 21st largest holding, accounting for 2.0% of its portfolio. Other institutional investors have also adjusted their holdings in the company, while analysts have issued a "Moderate Buy" consensus rating with an average price target of $563.50.
Puzo Michael J Purchases Shares of 15,907 Vertex Pharmaceuticals Incorporated $VRTX
Puzo Michael J has acquired a new stake of 15,907 shares in Vertex Pharmaceuticals (NASDAQ:VRTX), valued at approximately $7.9 million, making it 2% of their portfolio. Other institutional investors, including BlackRock Inc. and Capital Research Global Investors, also significantly increased their holdings. Despite a slight miss on adjusted earnings per share, Vertex Pharmaceuticals reported strong quarterly revenue growth of 12.5% year over year and maintains a "Moderate Buy" consensus rating from analysts with a target price of $563.50.
11,305 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by NewEdge Wealth LLC
NewEdge Wealth LLC has acquired 11,305 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) valued at approximately $5.62 million during the second quarter. Other institutional investors have also made significant moves in VRTX stock, with institutional ownership standing at 90.96%. The article also details recent stock performance, earnings, analyst ratings, and insider trading activity for Vertex Pharmaceuticals.
Knuff & Co LLC Purchases New Stake in Vertex Pharmaceuticals Incorporated $VRTX
Knuff & Co LLC has acquired a new stake of 14,288 shares, valued at approximately $7.1 million, in Vertex Pharmaceuticals (NASDAQ:VRTX) during the second quarter, making it the 18th biggest holding in their portfolio. Institutional investors and hedge funds collectively own 90.96% of the company, with several other firms also adjusting their stakes. Analyst sentiment remains positive with a consensus "Moderate Buy" rating and an average price target of $563.50, following recent price target increases from UBS, TD Cowen, and Truist Financial.
DCF Advisers LLC Invests $5.71 Million in Vertex Pharmaceuticals Incorporated $VRTX
DCF Advisers LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 11,500 shares valued at approximately $5.71 million, making it their 16th largest holding. Other institutional investors have also increased their stakes in Vertex. The article also details recent analyst ratings, insider trading activity, and Vertex Pharmaceuticals' financial performance and outlook.
E Fund Management Co. Ltd. Takes Position in Vertex Pharmaceuticals Incorporated $VRTX
E Fund Management Co. Ltd. has acquired a new stake in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 11,455 shares valued at approximately $5.69 million in the second quarter. This move comes as institutional investors collectively own 90.96% of the company's stock, despite recent insider selling of 10,464 shares worth about $4.96 million. Vertex Pharmaceuticals reported quarterly revenue of $3.33 billion, exceeding expectations, though its adjusted EPS of $4.73 slightly missed consensus estimates.
AssuredPartners Investment Advisors LLC Invests $2.06 Million in Vertex Pharmaceuticals Incorporated $VRTX
AssuredPartners Investment Advisors LLC recently acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX) during the second quarter, purchasing 4,147 shares valued at approximately $2.06 million. This investment comes amidst various analyst upgrades and downgrades, with the stock currently holding a "Moderate Buy" rating and an average price target of $563.50. Insider activity has also been noted, with executives selling shares totaling nearly $5 million over the past three months.
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Up by 4.48% on Aug 19: Drivers Behind the Movement
Vertex Pharmaceuticals Inc (VRTX) stock closed up by 4.48% on August 19, driven by the failure of a rival's cystic fibrosis clinical trial, strong Q2 revenue that beat estimates, and raised full-year guidance. The company's market leadership in cystic fibrosis and strategic diversification efforts have also contributed to bullish analyst ratings and increased institutional buying. Despite this, the company faces risks such as revenue concentration, operating expense pressure, and valuation premium.
The Bull Case For PTC Therapeutics (PTCT) Could Change Following Renal Data Progress For ST-920
PTC Therapeutics' bull case is potentially shifting due to positive renal data and regulatory progress for its gene therapy, ST-920, highlighted by a recent special call. This development underscores PTC's growing focus on rare disease gene therapies and portfolio diversification beyond its current commercial base. While the immediate future still relies on existing product performance, ST-920's advancement offers a new pillar for the company's long-term investment narrative and financial outlook.
Vertex Pharmaceuticals (NASDAQ:VRTX) Sets New 1-Year High - Here's What Happened
Vertex Pharmaceuticals (NASDAQ:VRTX) reached a new 52-week high of $546.86, with its market capitalization at approximately $138.62 billion. The company reported quarterly revenue of $3.33 billion, exceeding expectations, though earnings per share of $4.73 narrowly missed estimates. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $563.50, and institutional investors hold a significant 90.96% stake in the company.
0000875320-22-000017 | 8-K
This article details an 8-K SEC filing by Vertex Pharmaceuticals, Inc./MA. The filing, dated May 23, 2022, is a report of unscheduled material events or a corporate event. It provides access to the document in various formats including HTML, PDF, DOC, XLS, and XBRL, and is available through the Vertex Pharmaceuticals Newsroom.
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Vertex Pharmaceuticals Inc. (VRTX) saw its stock rise by 4.52% to $552.06, outperforming the broader market on a strong trading day. This marked the third consecutive day of gains for the company, as the S&P 500 Index and Dow Jones Industrial Average also posted modest increases.
Vertex Pharmaceuticals stock hits all-time high at 546.17 USD
Vertex Pharmaceuticals Inc. (VRTX) stock reached an all-time high of $546.17, reflecting a 38.31% increase over the past year and a 16.5% return year-to-date. Despite InvestingPro analysis suggesting the stock is overvalued, analysts from RBC Capital, Bernstein, Bank of America, Wolfe Research, and BMO Capital have reiterated positive ratings and price targets, citing the company's robust drug pipeline and strong market position, particularly with its Trikafta product. The biotech giant boasts a market capitalization of $138 billion and a "GREAT" financial health score.
Wealthfront Advisers LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX
Wealthfront Advisers LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX) during the second quarter, purchasing 41,608 shares valued at approximately $20.67 million. Other institutional investors have also recently adjusted their holdings in the pharmaceutical company. Vertex Pharmaceuticals has shown a 12.5% year-over-year revenue increase in its latest quarterly earnings, though it slightly missed EPS estimates.
Meeder Advisory Services Inc. Buys Shares of 6,415 Vertex Pharmaceuticals Incorporated $VRTX
Meeder Advisory Services Inc. has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX) by purchasing 6,415 shares valued at approximately $3,187,000 during the second quarter. Other institutional investors have also adjusted their holdings in the company, which has an average analyst rating of "Moderate Buy" and an average target price of $563.50. Despite some insider selling, the company reported solid quarterly revenues of $3.33 billion, exceeding analyst estimates.
Pallas Capital Advisors LLC Takes $1.09 Million Position in Vertex Pharmaceuticals Incorporated $VRTX
Pallas Capital Advisors LLC has initiated a new position in Vertex Pharmaceuticals (NASDAQ:VRTX) by acquiring 2,200 shares worth approximately $1.09 million during the second quarter. Vertex Pharmaceuticals has received a consensus "Moderate Buy" rating from analysts, with an average price target of $563.50, following a quarter where it exceeded revenue expectations but narrowly missed EPS estimates. Insider trading activity over the last three months shows sales totaling nearly $5 million, primarily through pre-arranged trading plans.
Danske Bank A S Takes $78.52 Million Position in Vertex Pharmaceuticals Incorporated $VRTX
Danske Bank A S has acquired a new position in Vertex Pharmaceuticals, purchasing 158,064 shares valued at approximately $78.52 million during the second quarter. This makes Danske Bank A S the owner of about 0.06% of the pharmaceutical company's stock. Other institutional investors like BlackRock Inc. and Norges Bank also significantly increased their stakes, bringing institutional ownership to 90.96%.
27,829 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Danica Pension Livsforsikringsaktieselskab
Danica Pension Livsforsikringsaktieselskab recently purchased 27,829 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) for approximately $13.823 million during the second quarter. Other institutional investors have also acquired stakes in the pharmaceutical company, with institutional ownership reaching 90.96%. Insider activity includes sales by EVP Ourania Tatsis and EVP Duncan Mckechnie, while analysts maintain a "Moderate Buy" consensus rating with an average price target of $563.50.
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains
Shares of Vertex Pharmaceuticals Inc. (VRTX) gained 2.45% on Tuesday, closing at $528.19. Despite this daily increase, the stock underperformed compared to the broader market, as the S&P 500 Index fell 0.69% and the Dow Jones Industrial Average dropped 0.22%. This marks the second consecutive day of gains for Vertex Pharmaceuticals.
UNIVEST FINANCIAL Corp Takes Position in Vertex Pharmaceuticals Incorporated $VRTX
UNIVEST FINANCIAL Corp has acquired a new stake in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 9,049 shares valued at approximately $4.495 million in the second quarter. This move is part of broader institutional investment activity in Vertex, which has seen numerous hedge funds and other institutional investors either establish new positions or adjust existing ones. Analyst ratings for Vertex Pharmaceuticals are predominantly positive, with a "Moderate Buy" consensus and an average price target of $563.50.
Perigon Wealth Management LLC Takes $4.39 Million Position in Vertex Pharmaceuticals Incorporated $VRTX
Perigon Wealth Management LLC recently acquired a new stake of 8,834 shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), valued at approximately $4.39 million. This move is part of broader institutional investment activity, with 90.96% of the stock owned by hedge funds and institutional investors. The article also details recent analyst ratings, stock performance, and insider trading activity for Vertex Pharmaceuticals.
Mitsubishi UFJ Asset Management Co. Ltd. Acquires New Shares in Vertex Pharmaceuticals Incorporated $VRTX
Mitsubishi UFJ Asset Management Co. Ltd. recently acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), purchasing 647,193 shares valued at approximately $321.48 million. This move positions the fund as a significant institutional investor in the pharmaceutical company. Other institutional investors have also adjusted their holdings, with hedge funds and institutional investors collectively owning 90.96% of the company's stock.
Citizens Financial Group Inc. RI Purchases New Stake in Vertex Pharmaceuticals Incorporated $VRTX
Citizens Financial Group Inc. RI has acquired a new stake of 50,988 shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), valued at approximately $25.33 million. This comes as other institutional investors have also adjusted their positions in VRTX, which currently has 90.96% institutional ownership. Vertex Pharmaceuticals recently reported earnings, missing consensus estimates by $0.01 per share but exceeding revenue expectations, while several analysts have raised their price targets for the stock.
Cornerstone Advisors LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX
Cornerstone Advisors LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 24,760 shares valued at approximately $12.3 million in the second quarter. Other institutional investors also adjusted their holdings, with 90.96% of the stock now owned by institutions. The pharmaceutical company recently reported quarterly earnings, missing consensus estimates slightly but showing a 12.5% year-over-year revenue increase.
Grandfield & Dodd LLC Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX
Grandfield & Dodd LLC has acquired a new stake of 24,838 shares in Vertex Pharmaceuticals (NASDAQ:VRTX), valued at approximately $12.34 million, during the second quarter. This investment is part of a broader trend where institutional investors and hedge funds are adjusting their positions in the pharmaceutical company. Additionally, insider transactions show recent sales by CMO Carmen Bozic and EVP Duncan Mckechnie, while the company's stock shows a 1.9% increase in trading and analysts maintain a "Moderate Buy" rating with an average target price of $563.50.
6,857 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Commerzbank Aktiengesellschaft FI
Commerzbank Aktiengesellschaft FI recently acquired a new stake of 6,857 shares in Vertex Pharmaceuticals (NASDAQ:VRTX), valued at approximately $3.41 million. Other institutional investors also adjusted their holdings in the pharmaceutical company. Analyst ratings show a consensus of "Moderate Buy" for VRTX, with an average price target of $563.50, while recent insider transactions reveal sales by company executives.
Deutsche Bank AG Invests $784.39 Million in Vertex Pharmaceuticals Incorporated $VRTX
Deutsche Bank AG has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 1,579,110 shares valued at approximately $784.39 million during the second quarter. This investment makes Deutsche Bank AG one of several institutional investors increasing their stakes in the pharmaceutical company. The article also details recent insider stock sales, financial performance, and analyst ratings for Vertex Pharmaceuticals.
Alphabet Inc. Makes New Investment in Spero Therapeutics, Inc. $SPRO
Alphabet Inc. has acquired a new stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) during the second quarter, purchasing 889,979 shares valued at approximately $1.97 million. This investment makes Spero Therapeutics about 0.0% of Alphabet's portfolio and represents 1.54% of SPRO's outstanding shares. Spero Therapeutics recently reported a quarterly loss that slightly beat analyst estimates, and the company currently holds a consensus "Hold" rating from analysts.
BlackRock Inc. Invests $11.98 Billion in Vertex Pharmaceuticals Incorporated $VRTX
BlackRock Inc. has acquired a significant new stake in Vertex Pharmaceuticals, purchasing 24.1 million shares valued at approximately $11.98 billion, which represents a 9.5% ownership. This move increases institutional ownership to over 90% of the company, which continues to receive a "Moderate Buy" consensus rating from analysts with an average price target of $563.50. Despite narrowly missing EPS estimates, Vertex Pharmaceuticals reported a 12.5% year-over-year revenue increase to $3.33 billion.
Latigo Nets $346 Million from Public Offering
Thousand Oaks-based Latigo Biotherapeutics Inc. successfully raised $346 million from its initial public offering on the Nasdaq stock exchange. The company, launched out of VC firm Westlake Village BioPartners, is focused on developing non-opioid pain drugs, with its lead candidate LTG-001 currently in preparation for Phase 3 clinical trials after receiving "fast-track" designation from the FDA and positive Phase 2 results. The IPO saw its stock price rise from $18 to $20 within five trading sessions.
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (CRNX) to Vertex Pharmaceuticals Incorporated (VRTX) for $85.00 per share in cash. KSF is scrutinizing whether this acquisition price and the process leading to it adequately value Crinetics Pharmaceuticals, Inc., encouraging shareholders who believe the offer undervalues the company to contact them for legal consultation.
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Vertex Pharmaceuticals Inc. (VRTX) saw its stock rise by 1.94% to $515.55 on Monday, despite a negative overall trading session for the stock market, which saw the S&P 500 Index and Dow Jones Industrial Average fall. This increase broke a three-day losing streak for the company's shares.
Satellos Bioscience Stock Drops 3.39% as Investors Weigh Duchenne Muscular Dystrophy Therapy, Clinical Development and Biotech Risk
Satellos Bioscience Inc. (TSX:MSCL) stock dropped 3.39% as investors evaluated its Duchenne muscular dystrophy (DMD) therapy, SAT-3247, against inherent clinical development risks and the competitive biotechnology landscape. The company, focused on muscle-regeneration through muscle stem cells, is a clinical-stage biotech whose valuation hinges on successful human clinical trial results and future commercialization potential. Key risks include development failure, significant financing needs, and intense competition in the DMD market, making it a speculative investment.
Plato Investment Management Ltd Purchases Shares of 6,083 Vertex Pharmaceuticals Incorporated $VRTX
Plato Investment Management Ltd recently acquired 6,083 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) valued at approximately $3 million during the second quarter. Other institutional investors have also increased their holdings, leading to institutions collectively owning 90.96% of the company's stock. Despite some insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $563.50, following a quarter where Vertex reported strong revenue growth but narrowly missed earnings estimates.
2,792 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by Simplicity Wealth LLC
Simplicity Wealth LLC recently acquired 2,792 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) valued at approximately $1.39 million during the second quarter. Vertex reported quarterly revenue of $3.33 billion, exceeding estimates, though its EPS of $4.73 narrowly missed consensus. The company holds a "Moderate Buy" rating from analysts with an average price target of $563.50, and institutional investors collectively own 90.96% of its stock.
Trivium Point Advisory LLC Takes Position in Vertex Pharmaceuticals Incorporated $VRTX
Trivium Point Advisory LLC has acquired a new stake in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 2,199 shares valued at approximately $1.092 million during the second quarter. Other institutional investors have also recently adjusted their holdings in the pharmaceutical company, which reported quarterly earnings that narrowly missed consensus estimates but showed a 12.5% year-over-year revenue increase. The company's stock performance shows a 12-month low of $374.17 and a high of $546.17, with analysts giving it a "Moderate Buy" consensus rating and a target price of $563.50.
Flputnam Investment Management Co. Invests $19.93 Million in Vertex Pharmaceuticals Incorporated $VRTX
Flputnam Investment Management Co. has acquired a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), purchasing 40,116 shares valued at approximately $19.93 million during the second quarter. Other institutional investors have also adjusted their holdings in the pharmaceutical company. Analyst ratings for VRTX are generally positive, with a consensus "Moderate Buy" rating and an average target price of $563.50, despite some recent insider stock sales.
Global Retirement Partners LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX
Global Retirement Partners LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX) during the second quarter, purchasing 3,925 shares valued at approximately $1,950,000. Several other institutional investors also adjusted their holdings in the pharmaceutical company. Vertex Pharmaceuticals has a market capitalization of $128.36 billion and recently reported quarterly earnings of $4.73 EPS, slightly missing analyst estimates, while revenue exceeded expectations.
Bank of America Corp DE Sells 85,189 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
Bank of America Corp DE has reduced its stake in Crinetics Pharmaceuticals (NASDAQ:CRNX) by selling 85,189 shares, now owning 716,125 shares valued at $26 million. Despite this, institutional investors collectively hold 98.51% of the stock. Crinetics Pharmaceuticals recently reported better-than-expected quarterly results with significant revenue growth, though it remains unprofitable and analysts generally maintain a "Hold" rating.
2,486,038 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by AIGH Capital Management LLC
AIGH Capital Management LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 2,486,038 shares valued at approximately $26.7 million in the second quarter, making it their 9th largest holding. Other institutional investors like Norges Bank and Bank of New York Mellon Corp also made significant investments. The article also details recent insider stock sales, analyst ratings, and Vertex Pharmaceuticals' stock performance and financial results, noting a slight earnings miss but a revenue beat.
Why AbCellera (ABCL) Is Up 64.2% After Menopause Trial Win, Equity Raise And Vertex Deal
AbCellera (ABCL) shares rose by 64.2% following positive Phase 2 results for its menopause drug ABCL635, a US$200 million equity raise, and a new collaboration with Vertex Pharmaceuticals. These developments aim to expand AbCellera's clinical pipeline, strengthen its funding, and diversify its revenue streams beyond a single asset. Despite these positive updates, the company's widening net losses and ongoing need for capital remain a concern for investors.
TFR Capital LLC. Takes Position in Vertex Pharmaceuticals Incorporated $VRTX
TFR Capital LLC. has acquired a new position of 5,074 shares in Vertex Pharmaceuticals (NASDAQ:VRTX) valued at approximately $2.52 million during the second quarter. Other institutional investors also adjusted their holdings in the pharmaceutical company, which now has 90.96% institutional ownership. Despite missing earnings estimates by $0.01 per share, Vertex Pharmaceuticals saw its revenue increase by 12.5% year over year, and analysts maintain a "Moderate Buy" rating with an average target price of $563.50.
S&CO Inc. Buys Shares of 4,103 Vertex Pharmaceuticals Incorporated $VRTX
S&CO Inc. recently acquired 4,103 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) worth approximately $2.04 million during the second quarter. This purchase contributes to institutional investors collectively owning 90.96% of Vertex's outstanding stock. Despite missing earnings per share estimates slightly, Vertex reported strong revenue growth and maintains a "Moderate Buy" analyst rating with a target price above its current trading value.
125,970 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by ABN AMRO Bank N.V.
ABN AMRO Bank N.V. has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 125,970 shares valued at approximately $62.52 million during the second quarter. Other hedge funds have also adjusted their holdings in the company, which is 90.96% owned by institutional investors. Vertex Pharmaceuticals recently reported quarterly earnings, missing analyst EPS estimates but exceeding revenue expectations, and the stock has a "Moderate Buy" consensus rating from analysts.
Why AbCellera (ABCL) Is Up 64.2% After Menopause Trial Win, Equity Raise And Vertex Deal
AbCellera Biologics (ABCL) saw its stock rise by 64.2% following positive Phase 2 results for its menopause drug ABCL635, a US$200 million equity raise, and a new collaboration with Vertex Pharmaceuticals. These developments strengthen its clinical pipeline and funding base, with the Vertex deal adding non-dilutive funding and a potential royalty stream. Despite these positive updates, the company still faces challenges with widening net losses and an ongoing need for capital.
Wave Life Sciences Inc (HAM:0VS) Stock Price, Trades & News
This page provides a detailed overview of Wave Life Sciences Inc (HAM:0VS) stock, including its current price (€4.96), market capitalization (€864.92M), and various financial metrics such as P/B ratio (2.17) and enterprise value. It highlights key financial strength, growth, momentum, liquidity, and profitability ranks, along with upcoming stock events and warnings about severe warning signs detected by GuruFocus. The company is described as a clinical-stage biotechnology firm focused on RNA medicines to treat rare and prevalent disorders.
Summit Global Investments Acquires Shares of 7,182 Vertex Pharmaceuticals Incorporated $VRTX
Summit Global Investments purchased 7,182 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in the second quarter, valued at approximately $3.57 million. Other hedge funds also adjusted their holdings, with institutional investors now owning 90.96% of the stock. Analysts currently have a "Moderate Buy" rating for VRTX with an average target price of $563.50.
